The scale of biopharmaceutical excipients in the Asia Pacific region is nearly 800 million US dollars
Release time:
2020-06-04 10:17
According to a new report released by market research firm Grand View Research, the Asia Pacific biopharmaceutical excipient market was approximately $473.72 million in 2017 and is expected to reach $791.4 million by 2025. During the forecast period, this market will grow at a compound annual growth rate (CAGR) of 6.63%.
The high investment in the research and development of biosimilars, as well as the gradual loss of patent protection for the best-selling biologics, are expected to drive market development. And novel excipients can increase process yield and promote new product research by reducing the production risks of biologics. The increasing demand for similar drugs is an indispensable part of biopharmaceutical products. The excipients used in biopharmaceutical products require specific properties, which help ensure the stability of the product. From 2020 to 2030, 17 biologics will lose patent protection, promoting the development of the biosimilar drug market. Due to the aging population growth, lifestyle changes, and accelerated urbanization process, there is a huge potential demand for biosimilars in the Asia Pacific region. At the same time, the above factors lead to a high incidence of non communicable diseases, such as diabetes, cancer and autoimmune diseases. In Asia, there is a huge patient population whose medical needs have not been met, and the penetration rate of market participants continues to increase, prompting the biopharmaceutical industry to carry out more research and development activities related to biosimilars.
Related News
L-Lysine HCL: High-Purity Pharmaceutical Grade Supply from Jirong Pharmaceutical 2026
This 2026 updated guide covers full details of L-Lysine HCL including its core definition, industry application scenarios, quality grading standards, verified sourcing tips, and frequently raised user questions, based on Jirong Pharmaceutical’s 22 years of amino acid production experience and latest industry research, to help global buyers select compliant, cost-effective products that match their specific formulation requirements.
L-Lysine HCL: Premium Pharmaceutical Grade Amino Acid 2026
This 2026 practical guide for L-Lysine HCL covers core definitions, production specifications, application scenarios, quality testing protocols, and supplier selection tips, based on Jirong Pharmaceutical’s decades of amino acid R&D and manufacturing experience. It integrates latest industry research, real production cases and regulatory compliance requirements, helping global pharma, health supplement and feed industry buyers find reliable, cost-effective qualified supplies.
Premium L-Lysine HCL: Uses, Quality Standards & Sourcing 2026 Guide
This 2026 comprehensive guide breaks down core properties, grade classification, industrial applications, quality testing protocols and B2B sourcing tips for L-Lysine HCL, combining Jirong Pharmaceutical’s 22-year production experience of GMP-certified amino acid products to help global buyers select qualified, cost-effective raw materials that meet USP, EP and FDA regulatory standards.
Premium L-Lysine HCL: High Purity Pharmaceutical Grade Amino Acid
This 2026 E-E-A-T compliant guide for L-Lysine HCL covers its core definition, key industrial use cases, quality testing protocols, sourcing best practices and common industry questions. Backed by Jirong Pharmaceutical's 18 years of amino acid manufacturing experience, it provides authoritative, practical data to help formulators, bulk buyers and R&D teams make evidence-based procurement and product development decisions.
L-Lysine HCL: Premium Pharma Grade Amino Acid from Jirong Pharmaceutical
This comprehensive guide outlines core definitions, verified specifications, cross-industry applications, quality testing protocols, safety guidelines and 2026 market insights for L-Lysine HCL, leveraging Jirong Pharmaceutical’s on-site production experience to help global buyers make compliant, cost-effective procurement decisions aligned with latest regulatory requirements.
Premium Pharmaceutical Grade L-Lysine HCL 2026 | Jirong Pharmaceutical Complete Guide
This 2026 updated guide systematically introduces core attributes, production standards, application scenarios, purchasing tips and frequently asked questions of L-Lysine HCL. Backed by Jirong Pharmaceutical’s 14 years of amino acid manufacturing experience, it offers authoritative data to help B2B buyers select qualified high-quality L-Lysine HCL products easily.
Shijiazhuang Jirong Pharmaceutical Co., Ltd.
Address: No.8 North of Huagong Road, Circular Chemical Industry Zone, Shijiazhuang, Hebei, China
Sales line:86-0311-85157950
